Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

Bruno Sangro; Aiwu Ruth He; Thomas Yau; Chiun Hsu; Yoon‐Koo Kang; Tae‐You Kim; Armando Santoro; Ignacio Melero; Masatoshi Kudo; M. Ho; Ana Matilla; Francesco Tovoli; Jennifer J. Knox; Bassel F. El‐Rayes; Mirelis Rivera Acosta; Jaclyn Neely; Yun Shen; Marina Tschaika; Anthony El-Khoureiry

doi:10.1016/s0168-8278(20)30760-1

Related publications

Article2020

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.

Aiwu Ruth He, Thomas Yau, Chiun Hsu, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Jaclyn Neely, Yun Shen, Marina Tschaika, Anthony B. El-Khoueiry

Article2019

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Jaclyn Neely, Yun Shen, Carlos Baccan, Christine Marie Dela Cruz, Chiun Hsu

Article2024

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Ignacio Melero, Thomas Yau, Yoon‐Koo Kang, T.-Y. Kim, Armando Santoro, B. Sangro, Masatoshi Kudo, Ming Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, M. Acosta-Rivera, Ho Yeong Lim, S. Soleymani, J. Yao, Jaclyn Neely, M. Tschaika, Chiun Hsu, Anthony B. El-Khoueiry

Article2023

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (<scp>CheckMate</scp> 040)

Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Feng Yan, Ling Gao, Urvi Aras

Article2021

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.

Anthony B. El-Khoueiry, Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho Yeong Lim, Arteid Memaj, Ashwin R. Sama, Chiun Hsu